Skip to main content
Clinical Trials/NCT06471972
NCT06471972
Recruiting
Not Applicable

Biomarkers After Out-of-hospital Cardiac Arrest- a STEPCARE Substudy

Region Skane4 sites in 2 countries1,000 target enrollmentOctober 1, 2023
ConditionsCardiac Arrest

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiac Arrest
Sponsor
Region Skane
Enrollment
1000
Locations
4
Primary Endpoint
Functional outcome according to the modified Rankin Scale
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

A prospective multicenter biomarker study with adult patients treated on

intensive care units after out-of-hospital cardiac arrest. Patients will be recruited from specific sites participating in the Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation (STEPCARE) trial. (ClinicalTrials.gov ID NCT05564754).

Blood samples will be collected at 12, 24, 48, and 72 hours after randomization in selected sites, aliquoted and frozen on-site. After trial completion, samples will be stored in a central biobank. Sample analysis will be performed in batch after trial completion. Functional outcome will be assessed at 30 days and 6 months after cardiac arrest.

Detailed Description

A prospective multicenter biomarker study with adult patients treated on intensive care units after out-of-hospital cardiac arrest. Patients will be recruited from specific sites participating in the Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation (STEPCARE) trial. (ClinicalTrials.gov ID NCT05564754). The STEPCARE-trial is a 2x2x2 randomised trial studying patients who have been resuscitated from cardiac arrest and who are comatose. It will include three different interventions focusing on sedation targets, temperature targets and mean arterial pressure targets. 3500 patients who are comatose after cardiac arrest will be included in the STEPCARE trial studying three separate targets. All patients will be randomised to a control or an intervention arm for sedation, temperature and blood pressure targets as follows: * Continuous deep sedation for 36 hours or minimal sedation (SEDCARE) * Fever management with or without a feedback-controlled device (TEMPCARE) * A mean arterial pressure target of \>85mmHg or \>65mmHg. (MAPCARE) Hospitals participating in the STEPCARE trial may opt to participate in the biomarker substudy if they include \>20 patients/year, have the possibility to collect and process samples 24/7. Processing should be done by professional or experienced personnel. Blood samples will be collected at 12, 24, 48, and 72 hours after randomization in selected sites, aliquoted and frozen on-site. Serum, plasma and PAX-RNA vials are collected. After trial completion, samples will be stored in a central biobank. Sample analysis will be performed in batch after trial completion. Functional outcome will be assessed at 30 days and 6 months after cardiac arrest. Primary outcome is poor functional outcome (modified Rankin Scale 4-6) at six months. Secondary outcomes are poor functional outcome at 30 days and survival at 6 months.

Registry
clinicaltrials.gov
Start Date
October 1, 2023
End Date
December 31, 2029
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • From sites participating in the STEPCARE biomarker substudy and withOut-of-hospital cardiac arrest
  • Sustained ROSC - defined as 20 minutes with signs of circulation without the need for chest compressions
  • Unconsciousness defined as not being able to obey verbal commands (FOUR-score motor response of \<4) or being intubated and sedated because of agitation after sustained ROSC.
  • Eligible for intensive care without restrictions or limitations
  • Inclusion within 4 hours of ROSC

Exclusion Criteria

  • On ECMO prior to randomization
  • Pregnancy
  • Suspected or confirmed intracranial hemorrhage
  • Previously randomized in the STEPCARE trial.

Outcomes

Primary Outcomes

Functional outcome according to the modified Rankin Scale

Time Frame: 6 months after randomisation

Poor functional outcome modified Rankin Scale 4-6 (moderately severe disability, severe disability or death). A higher score indicates a worse score.

Secondary Outcomes

  • Functional outcome according to the modified Rankin Scale(30 days after randomisation)
  • Mortality at 6 months(6 months after randomisation)

Study Sites (4)

Loading locations...

Similar Trials